Fate Ebitda vs Research Development Analysis
FATE Stock | USD 3.71 0.01 0.27% |
Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Ebitda and its Research Development accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
Ebitda vs Research Development
Ebitda vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Ebitda account and Research Development. At this time, the significance of the direction appears to have pay attention.
The correlation between Fate Therapeutics' Ebitda and Research Development is -0.98. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Research Development in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Ebitda and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Fate Therapeutics are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebitda i.e., Fate Therapeutics' Ebitda and Research Development go up and down completely randomly.
Correlation Coefficient | -0.98 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Ebitda
Research Development
Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.5M | 5.8M | 6.7M | 7.1M | Depreciation And Amortization | 1.3M | 13.8M | 18.3M | 19.2M |
Fate Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Fate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fate Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Short Long Term Debt Total | 26.9M | 97.3M | 114.8M | 109.3M | 103.5M | 108.7M | |
Other Current Liab | 17.5M | 54.8M | 45.6M | 57.9M | 27.5M | 18.9M | |
Total Current Liabilities | 27.8M | 85.6M | 81.3M | 114.1M | 39.1M | 36.6M | |
Total Stockholder Equity | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 210.3M | |
Other Liab | 4.5M | 58.5M | 52.1M | 3.9M | 4.4M | 4.2M | |
Property Plant And Equipment Net | 22.8M | 67.1M | 70.7M | 66.1M | 158.5M | 166.4M | |
Current Deferred Revenue | 2.8M | 21.1M | 21.5M | 42.2M | 685K | 650.8K | |
Net Debt | (72.9M) | (70.0M) | (18.8M) | 48.0M | 61.7M | 64.7M | |
Retained Earnings | (383.5M) | (556.9M) | (769.1M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.3M | 8.6M | 8.3M | 4.7M | 4.0M | |
Cash | 99.8M | 167.3M | 133.6M | 61.3M | 41.9M | 39.8M | |
Non Current Assets Total | 75.2M | 128.1M | 288.0M | 203.5M | 174.7M | 183.4M | |
Non Currrent Assets Other | 13.0M | 32.3M | 116.7M | 132.5M | 9.0K | 8.5K | |
Other Assets | 1.6M | 95.8M | 25.1M | 22.5M | 1.0 | 0.95 | |
Cash And Short Term Investments | 221.4M | 482.9M | 615.9M | 436.2M | 315.2M | 224.2M | |
Common Stock Total Equity | 65K | 76K | 88K | 96K | 110.4K | 115.9K | |
Common Stock Shares Outstanding | 68.2M | 82.4M | 94.7M | 96.8M | 98.4M | 54.2M | |
Liabilities And Stockholders Equity | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Non Current Liabilities Total | 29.7M | 152.4M | 161.3M | 107.6M | 98.7M | 63.3M | |
Other Current Assets | 4.3M | 5.9M | 8.8M | 27.4M | 13.6M | 14.3M | |
Other Stockholder Equity | 628.2M | 941.2M | 1.4B | 1.5B | 1.6B | 1.7B | |
Total Liab | 57.5M | 238.0M | 242.6M | 221.6M | 137.8M | 99.9M | |
Property Plant And Equipment Gross | 34.2M | 99.4M | 70.7M | 66.1M | 206.1M | 216.4M | |
Total Current Assets | 227.1M | 494.3M | 633.4M | 502.1M | 331.5M | 234.9M | |
Accumulated Other Comprehensive Income | 22K | 70K | (762K) | (1.9M) | 15K | 15.8K | |
Short Term Debt | 1.7M | 3.4M | 5.6M | 5.6M | 6.2M | 4.6M | |
Common Stock | 76K | 88K | 96K | 97K | 99K | 58.1K | |
Property Plant Equipment | 11.4M | 32.3M | 162.2M | 176.1M | 202.5M | 212.6M | |
Net Tangible Assets | 274.5M | 536.9M | 678.8M | 483.9M | 556.5M | 584.4M | |
Retained Earnings Total Equity | (285.4M) | (383.5M) | (556.9M) | (769.1M) | (692.2M) | (657.6M) | |
Short Term Investments | 121.6M | 315.6M | 482.3M | 374.9M | 273.3M | 159.4M | |
Capital Surpluse | 445.8M | 628.2M | 941.2M | 1.4B | 1.7B | 1.7B | |
Deferred Long Term Liab | 1.3M | 13.5M | 9.9M | 7.2M | 8.3M | 5.0M | |
Non Current Liabilities Other | 175K | 549K | 702K | 800K | 920K | 721.9K | |
Net Invested Capital | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 381.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
CEOs Directory Screen CEOs from public companies around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 0.065 | Quarterly Revenue Growth (0.97) | Return On Assets (0.21) | Return On Equity (0.42) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.